Evidence map›Paper›PMID 19079648›Full record

ArticleInternational journal of clinical and experimental pathology2009

Mass spectrometry-based proteomics and peptidomics for biomarker discovery in neurodegenerative diseases.

Xin Wei, Lingjun Li

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Xin WeiDepartment of Chemistry, University of Wisconsin, Madison, Wisconsin 53705, USA.
Lingjun Li
University of Wisconsin System · US

Funding

A Proteomic Approach to Biomarker Discovery in Prion DiseaseR21AI072588 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2007 to 2009
$380k
NIAID NIH HHS R21 AI072588
6 · The paper itself

Abstract

There is an urgent need to search for biomarkers that are indicative of neurodegenerative diseases, as the clinical diagnosis of which remains unsatisfactory. Mass spectrometry (MS) has been playing an important role in studying peptide and protein identities, structures, modifications and interactions that collectively drive their biological functions. MS-based proteomics technology is thus well suited for the biomarker discovery. This article reviews the overall strategies and workflows employed for biomarker discovery and recent applications of MS-based proteomics in neurodegenerative diseases. Special emphasis is placed on the studies of protein post-translational modification pattern changes and differential peptidomics under these pathological conditions.

Indexed as

Biomarkermass spectrometryneurodegenerative diseasespeptidomicspost-translational modificationsproteomics

Identifiers

PMID19079648
PMCPMC2583631
OpenAlexW1539981706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.